Lytix Biopharma today announces that the European Patent Office has granted patent no. 3229823B2 that covers the use of Lytix Biopharma’s leading drug candidate, LTX-315, in combination with a chemotherapeutic agent. The US member of this family has also recently been granted patent (patent no. 11123398B2), thus the family is now granted patent in major markets, including, in addition to Europe and USA, Japan.

Dr. Øystein Rekdal, CEO of Lytix Biopharma, comments: “The grant of this European patent is an important milestone in our Intellectual Property (IP) strategy and further strengthens our business case, as securing IP rights is critical for the protection of Lytix’ technology platform and the long-term value generation of the company”.